WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD Disclosure


WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On April16, 2019, Wave Life Sciences Ltd. (the Company or Wave) issued a press release announcing the final results from its Phase 1 clinical trial of investigational suvodirsen (WVE-210201) in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping; details on the design of its planned Phase 2/3 clinical trial of suvodirsen in DMD, DYSTANCE 51; and providing an update on the Companys ongoing open-label extension study of suvodirsen. The press release also indicated that the Phase 1 data and DYSTANCE 51 clinical trial details will be presented on April16, 2019 at the 2019 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Orlando, FL.

In addition, the press release indicated that Wave management will host an investor conference call at 7:30 a.m. ET on April16, 2019 to discuss the Phase 1 results and Phase 2/3 trial design. For purposes of the call, the Company provided an investor slide presentation (the Investor Slide Presentation) summarizing the Phase 1 results and Phase 2/3 trial design, which is available on the For Investors Media section of the Companys website at http://ir.wavelifesciences.com/. Copies of the press release and the Investor Slide Presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein.

Item 7.01 Other Events.

The information set forth in the press release dated April16, 2019, other than the second and sixth paragraphs thereof, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

Item 7.01 Financial Statements and Exhibits.

(d) Exhibits.

Investor Slide Presentation dated April16, 2019

The portions of the press release incorporated by reference into Item 7.01 of this Current Report on Form 8-K are being filed to such item. The remaining portions of the press release are being furnished to Item 7.01 of this Current Report on Form 8-K and shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Wave Life Sciences Ltd. Exhibit
EX-99.1 2 d735229dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference Phase 2/3 clinical trial for suvodirsen in DMD expected to initiate in July 2019 Interim efficacy data from ongoing open-label extension study expected in H2 2019 Investor conference call scheduled for 7:30 a.m. ET today to discuss Phase 1 results and Phase 2/3 trial design CAMBRIDGE,…
To view the full exhibit click here


WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb.